Providing Answers, Support and Hope in Pennsylvania, Delaware and Southern New Jersey
Encouraging New Developments Reported on Investigational Therapy, CLN-978, for Treatment of Systemic Lupus Erythematosus
New data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress of the investigational therapy, CLN-978, currently in Phase 1 study show clinical benefit, including remissions, after a single target dose of CLN-978 in people with refractory systemic lupus erythematosus (SLE) and difficult-to-treat rheumatoid arthritis (RA).
CLN-978 is a novel T cell engager designed to target and destroy disease-causing B cells and has the potential to be a convenient, off-the-shelf, subcutaneously delivered treatment option. Early results confirm deep, dose-dependent B cell depletion in peripheral blood and tissue. The favorable safety profile and clear dose-dependent response reinforce the potential of CLN-978 as a disease-modifying therapy for challenging autoimmune diseases.
Ongoing studies of multi-dose regimens aim to advance CLN-978 quickly through global clinical development to bring this new option to people with SLE and RA. Further data, including data from the first RA multi-dose cohort, will be shared at an Immunology Day hosted by Cullinan Therapeutics on June 10. Learn more about T-cell engagers here. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.